Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels

Realizing the reported misuse of human growth hormone (GH), investigation of a safe alternative mechanism for increasing endogenous GH is needed. Several GH secretagogues are available, including GH-releasing peptides (GHRPs) GHRP-2 and GHRP-6, and the GH-releasing hormone analog, sermorelin (SERM)....

Full description

Bibliographic Details
Main Authors: John T. Sigalos, Alexander W. Pastuszak, Andrew Allison, Samuel J. Ohlander, Amin Herati, Mark C. Lindgren, Larry I. Lipshultz
Format: Article
Language:English
Published: SAGE Publishing 2017-11-01
Series:American Journal of Men's Health
Online Access:https://doi.org/10.1177/1557988317718662
id doaj-cf3ac61894e146eb8f896c2c3fb897c1
record_format Article
spelling doaj-cf3ac61894e146eb8f896c2c3fb897c12020-11-25T03:03:14ZengSAGE PublishingAmerican Journal of Men's Health1557-98831557-98912017-11-011110.1177/1557988317718662Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 LevelsJohn T. Sigalos0Alexander W. Pastuszak1Andrew Allison2Samuel J. Ohlander3Amin Herati4Mark C. Lindgren5Larry I. Lipshultz6Baylor College of Medicine, Houston, TX, USAScott Department of Urology, Baylor College of Medicine, Houston, TX, USAScott Department of Urology, Baylor College of Medicine, Houston, TX, USAUniversity of Illinois at Chicago College of Medicine, Chicago, IL, USAThe Brady Urological Institut, John’s Hopkins Bayview Medical Center Baltimore, MD, USAUniversity of Oklahoma College of Medicine, Department of Urology, Oklahoma City, OK, USAScott Department of Urology, Baylor College of Medicine, Houston, TX, USARealizing the reported misuse of human growth hormone (GH), investigation of a safe alternative mechanism for increasing endogenous GH is needed. Several GH secretagogues are available, including GH-releasing peptides (GHRPs) GHRP-2 and GHRP-6, and the GH-releasing hormone analog, sermorelin (SERM). Insulin-like growth factor 1 (IGF-1) serves as a surrogate marker for GH. Here, the effect of GHRP/SERM therapy on IGF-1 levels is evaluated. A retrospective review of medical records was performed for 105 men on testosterone (T) therapy seeking increases in lean body mass and fat loss who were prescribed 100 mcg of GHRP-6, GHRP-2, and SERM three times daily. Compliance with therapy was assessed, and 14 men met strict inclusion criteria. Serum hormone levels of IGF-1, T, free T (FT), estradiol (E), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were evaluated. Mean (SD) age of the cohort was 33.2 (2.9) years, and baseline IGF-1 level was 159.5 (26.7) ng/mL. Mean (SD) duration of continuous GHRP/SERM treatment was 134 (88) days. Mean posttreatment IGF-1 level was 239.0 (54.6) ng/mL ( p < .0001). Three of the 14 men were on an aromatase inhibitor and/or tamoxifen prior to treatment and another 4 men were coadministered an aromatase inhibitor and/or tamoxifen during treatment. Inhibition of E production or estrogen receptor blockade resulted in smaller increases in IGF-1 levels. GHRP/SERM therapy increases serum IGF-1 levels with strict compliance to thrice-daily dosing. The results suggest that combination therapy may be beneficial in men with wasting conditions that can improve with increased GH secretion.https://doi.org/10.1177/1557988317718662
collection DOAJ
language English
format Article
sources DOAJ
author John T. Sigalos
Alexander W. Pastuszak
Andrew Allison
Samuel J. Ohlander
Amin Herati
Mark C. Lindgren
Larry I. Lipshultz
spellingShingle John T. Sigalos
Alexander W. Pastuszak
Andrew Allison
Samuel J. Ohlander
Amin Herati
Mark C. Lindgren
Larry I. Lipshultz
Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels
American Journal of Men's Health
author_facet John T. Sigalos
Alexander W. Pastuszak
Andrew Allison
Samuel J. Ohlander
Amin Herati
Mark C. Lindgren
Larry I. Lipshultz
author_sort John T. Sigalos
title Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels
title_short Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels
title_full Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels
title_fullStr Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels
title_full_unstemmed Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels
title_sort growth hormone secretagogue treatment in hypogonadal men raises serum insulin-like growth factor-1 levels
publisher SAGE Publishing
series American Journal of Men's Health
issn 1557-9883
1557-9891
publishDate 2017-11-01
description Realizing the reported misuse of human growth hormone (GH), investigation of a safe alternative mechanism for increasing endogenous GH is needed. Several GH secretagogues are available, including GH-releasing peptides (GHRPs) GHRP-2 and GHRP-6, and the GH-releasing hormone analog, sermorelin (SERM). Insulin-like growth factor 1 (IGF-1) serves as a surrogate marker for GH. Here, the effect of GHRP/SERM therapy on IGF-1 levels is evaluated. A retrospective review of medical records was performed for 105 men on testosterone (T) therapy seeking increases in lean body mass and fat loss who were prescribed 100 mcg of GHRP-6, GHRP-2, and SERM three times daily. Compliance with therapy was assessed, and 14 men met strict inclusion criteria. Serum hormone levels of IGF-1, T, free T (FT), estradiol (E), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were evaluated. Mean (SD) age of the cohort was 33.2 (2.9) years, and baseline IGF-1 level was 159.5 (26.7) ng/mL. Mean (SD) duration of continuous GHRP/SERM treatment was 134 (88) days. Mean posttreatment IGF-1 level was 239.0 (54.6) ng/mL ( p < .0001). Three of the 14 men were on an aromatase inhibitor and/or tamoxifen prior to treatment and another 4 men were coadministered an aromatase inhibitor and/or tamoxifen during treatment. Inhibition of E production or estrogen receptor blockade resulted in smaller increases in IGF-1 levels. GHRP/SERM therapy increases serum IGF-1 levels with strict compliance to thrice-daily dosing. The results suggest that combination therapy may be beneficial in men with wasting conditions that can improve with increased GH secretion.
url https://doi.org/10.1177/1557988317718662
work_keys_str_mv AT johntsigalos growthhormonesecretagoguetreatmentinhypogonadalmenraisesseruminsulinlikegrowthfactor1levels
AT alexanderwpastuszak growthhormonesecretagoguetreatmentinhypogonadalmenraisesseruminsulinlikegrowthfactor1levels
AT andrewallison growthhormonesecretagoguetreatmentinhypogonadalmenraisesseruminsulinlikegrowthfactor1levels
AT samueljohlander growthhormonesecretagoguetreatmentinhypogonadalmenraisesseruminsulinlikegrowthfactor1levels
AT aminherati growthhormonesecretagoguetreatmentinhypogonadalmenraisesseruminsulinlikegrowthfactor1levels
AT markclindgren growthhormonesecretagoguetreatmentinhypogonadalmenraisesseruminsulinlikegrowthfactor1levels
AT larryilipshultz growthhormonesecretagoguetreatmentinhypogonadalmenraisesseruminsulinlikegrowthfactor1levels
_version_ 1724686843874639872